PCI Biotech and Immunicum Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments
30 Noviembre 2021 - 1:00AM
PCI Biotech and Immunicum Announce an Extension to Their Research
Collaboration to Explore Novel Cancer Vaccination Treatments
Oslo, Norway, November 30, 2021 - PCI Biotech
Holding ASA (OSE: PCIB), a cancer focused biopharmaceutical company
with a unique intracellular delivery technology via Photochemical
Internalisation and Immunicum AB (publ; IMMU.ST), a
biopharmaceutical company focused on hard-to-treat established
tumors and the prevention of cancer recurrence, announced today an
extension of their current collaboration.
The companies jointly research the possibility
to overcome current hurdles in cancer immunotherapy by introducing
tumor independent immune targets into the tumor microenvironment,
in combination with vaccination or adoptive immunotherapies. The
so-called Tumor Independent Antigen concept, which has been
invented by Immunicum, could benefit from PCI Biotech’s antigen
delivery technologies based on Photochemical Internalisation.
Following the encouraging results of the first set of in vitro
experiments, during which the delivery protocol of the combination
treatment has been optimized, the companies have decided to move
ahead to evaluate the novel therapeutic concept in animal models.
While the first experiments were conducted by Immunicum, this
further in vivo evaluation will be carried out by PCI Biotech.
Commenting on the announcement PCI Biotech’s
CEO, Per Walday said: “The results of the initial collaborative
experiments are encouraging, supporting the immune response
enhancing capability of the fimaVacc platform technology. We are
committed to this collaboration and are looking forward to the next
series of experiments in animal models, which are aimed to generate
data that could pave the way to a potential joint development
program.”
Erik Manting, CEO of Immunicum added: “At
Immunicum, we are continuously studying novel immunotherapy
concepts aimed to address hard-to-treat established tumors and to
overcome the limitations of currently available cancer therapies.
In this collaboration, we are combining our know-how and technology
basis with that of PCI Biotech to design potential novel
therapeutic concepts and we look forward to advancing the
collaboration through in vivo studies as an important next
step.”
Please see attachment for the full press
release.
Contact
information: Per
Walday,
CEO pw@pcibiotech.noMobile:
+47 917 93 429
About
Immunicum
AB Immunicum
is a biopharmaceutical company focused on hard-to-treat established
tumors and the prevention of cancer recurrence, two key challenges
in oncology. We are leveraging our unparalleled expertise in
allogeneic dendritic cell biology to develop an advanced clinical
pipeline of novel, off-the-shelf, cell-based therapies for solid
and blood-borne tumors. Based in Sweden and the Netherlands,
Immunicum is publicly traded on the Nasdaq Stockholm.
www.immunicum.com
About PCI
Biotech PCI
Biotech is a biopharmaceutical late-stage clinical development
company focusing on development and commercialisation of novel
therapies for the treatment of cancer through its innovative
photochemical internalisation (PCI) technology platform. PCI is
applied to three distinct anticancer paradigms:
fimaChem (enhancement of
chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction
technology for therapeutic vaccination), and
fimaNAc (nucleic acid
therapeutics delivery).
Photochemical internalisation induces triggered
endosomal release that is used to unlock the true potential of a
wide array of therapeutic modalities. The company’s lead programme
fimaChem consists of
a pivotal study in bile duct cancer, an orphan indication with
a high unmet need and without approved products.
fimaVacc applies a unique mode of
action to enhance the essential cytotoxic effect of therapeutic
cancer vaccines, which works in synergy with several other
state-of-the-art vaccination technologies.
fimaNAc utilises the endosomal
release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major
bottlenecks facing this emerging and promising field.
For further information, please visit:
www.pcibiotech.com
Forward-looking
statements This
announcement may contain forward-looking statements, which as such
are not historical facts, but are based upon various assumptions,
many of which are based, in turn, upon further assumptions. These
assumptions are inherently subject to significant known and unknown
risks, uncertainties and other important factors. Such risks,
uncertainties, contingencies and other important factors could
cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking
statements. PCI Biotech disclaims any obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024